Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment |
March 09, 2022 | March 2022 Bond Updates |
Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection) In the key secondary endpoint, efanesoctocog alfa demonstrated superiority in prevention of bleeding episodes, showing a... |
View more at: https://www.prnewswire.com:443/news-releases/efanesoctocog-alfa-met-primary-and-key-secondary-endpoints-in-pivotal-study-in-haemophilia-a-demonstrating-superiority-to-prior-factor-prophylaxis-treatment-301498753.html |
Related News |